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Formation of neurospheres (NS) in cultures of glioblastomas (GBMs), with self-renewal, clonogenic capacities, and tumorigenicity
following transplantation into immunodeficient mice, may denounce the existence of brain tumor stem cells (BTSCs) in vivo.
In sixteen cell lines from resected primary glioblastomas, NS showed the same genetic alterations as primary tumors and
the expression of stemness antigens. Adherent cells (AC), after adding 10% of fetal bovine serum (FBS) to the culture, were
genetically different from NS and prevailingly expressed differentiation antigens. NS developed from a highly malignant tumor
phenotype with proliferation, circumscribed necrosis, and high vessel density. Beside originating from transformed neural stem
cells (NSCs), BTSCs may be contained within or correspond to dedifferentiated cells after mutation accumulation, which reacquire
the expression of stemness antigens.
1. Introduction
In leukemias, rare tumor cells show extensive proliferative
and self-renewal potential and are responsible for main-
taining the tumor clone [1]; similar cells were subsequently
described in gliomas [2–4]. They were called brain tumor
stem cells (BTSCs), believed to be responsible for tumor
growth, recurrence and resistance to therapies and, suppos-
edly, to derive from neural stem cells (NSCs) transformation
and to be related to restricted unipotent or multipotent pro-
genitors [5–7]. They share with NSCs antigenic properties
of stemness, such as Nestin, Musashi-1, CD133, and SOX2
expression [8]; it has been suggested to better identify them
on the basis of their functional competence than as cell types
[9]. A derivation from dedifferentiated tumor cells that re-
acquire stem cell-like properties has also been hypothesized
[3, 10, 11].
Beside common antigenic properties with NSCs, BTSCs
share genetic properties with primary tumor cells. Their exis-
tence in tumors is indirectly demonstrated by the generation,
from tumor samples put in culture, of neurospheres (NS)
and, by adding 10% of fetal bovine serum (FBS), of adherent
cells (AC) with different capacities of self-renewal, differenti-
ation, clonogenicity, and tumorigenicity. The demonstration
of BTSCs in vitro may be influenced by the methodological
procedures employed and may have different expression mo-
dalities [12, 13]. For example, using N29 and N32 tumor
models, it has been demonstrated that NS formation is not
necessary to enrich for tumorigenic cells, due to the fact that
AC can display high clonogenicity in vitro, tumorigenicity
in vivo, and high expression of CD133 and Nestin [14].
Recently, two transcription factors have been proposed
as putative markers of stemness: sex determining region of Y
chromosome (Sry)-related highmobility group box2 (SOX2)
and repressor element-1 silencing transcription/neuron-re-
strictive silencer factor (REST/NRSF). SOX2 belongs to a
family of transcription factors expressed in the central nerv-
ous system (CNS) at early stages of development [15] and
it is expressed in malignant gliomas at both mRNA and
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Table 1: List of antibodies.
Antibody Source Dilution IHC Dilution WB Code Company
Nestin∗,◦ Mouse 1 : 200 — MAB5326 Chemicon
Nestin∗,◦ Rabbit 1 : 200 1 : 1000 AB5922 Chemicon
GFAP◦ Mouse 1 : 200 — M0761 DakoCytomation
GFAP◦ Rabbit 1 : 200 1 : 1000 Z0334 DakoCytomation
CD133◦ Mouse 1 : 20 1 : 250 130-090-422 Miltenyi Biotec
Musashi-1◦ Rabbit 1 : 200 1 : 500 AB5977 Chemicon
SOX2∗,◦ Rabbit 1 : 50 — sc-20088 Santa Cruz Biotec.
SOX2∗,◦ Mouse 1 : 100 1 : 250 MAB2018 R&D Systems
REST∗,◦ Rabbit 1 : 150 — IHC-00141 Bethyl Laboratories
REST Rabbit — 1 : 2500 A300-540A Bethyl Laboratories
GalC∗,◦ Mouse 1 : 200 — MAB342 Chemicon
βIII-Tubulin∗,◦ Mouse 1 : 250 — MAB1637 Chemicon
Ki-67/MIB-1∗ Mouse 1 : 100 — M7240 DakoCytomation
MGMT Mouse — 1 : 400 MS-470-P0 Lab Vision Corp.
α-Tubulin Rabbit — 1 : 5000 LF-PA0146 LabFrontier
CD34 Mouse Pre-diluted — 790-2927 Ventana
∗
HIER required.
◦Tested by IF.
protein level [16]. The second putative marker is REST/
NRSF (REST), which represses transcription of several neu-
ronal genes by binding to a DNA regulatory motif known
as repressor element 1/neuron-restrictive silencer element
(RE1/NRSE) [17]. REST is highly expressed in NSCs and its
transcription is blocked as they exit the cell cycle and dif-
ferentiate [18].
There is no possibility to demonstrate the existence of
BTSCs in tumors before surgical intervention as to be useful
for therapeutic strategies. Specific phenotypes have been
shown to be related with the derivation of NS from surgical
samples [19, 20], but it has not yet been definitively estab-
lished whether the phenotypical heterogeneity influences
[21] or not [22] the occurrence of BTSCs.
In a series of GBMs we wanted to verify from the genetic
and antigenic point of view the relationship between NS with
AC and the primary tumor phenotype.
2. Materials and Methods
2.1. Patients. The investigation was carried out on 16 par-
tially resected primary hemispheric GBMs (CV1-20) oper-
ated on at the Department of Neuroscience, Neurosurgical
Unit, University of Turin. Histological diagnosis of GBM was
performed according toWHO guidelines [23]. The mean age
of the patients was 62 years (range: 23–76 years). Ten patients
were males, and 6 were females.
The patient stratification was as follows: out of 16GBM
patients, 10 received postoperative standard radiation ther-
apy (RT) (60Gy total dose in 27–30 fractions administered
via a LINAC). Among the 10 irradiated patients, 8 received
standard Temozolomide (TMZ) therapy (75mg/m2/daily for
6 weeks), followed by adjuvant TMZ (200mg/m2 from day 1
to day 5 every 4 weeks for 6–12 cycles). Two patients received
TMZ, but no radiation therapy. Of the remaining patients,
2 did not receive any treatment because of low Karnofsky
Performance Status (KPS), and 2 were lost at follow up. All
patients are still alive with the exception of 2 patients who
died 3 months following surgery.
A viable sample from the dissected tumor was divided
into three serial slices: one was stored at−80◦C for molecular
genetics and frozen sections, one was fixed in buffered-for-
malin and embedded in paraffin (FFPE) and one was washed,
minced, and enzymatically dissociated for expansion in cul-
ture. A peripheral blood sample was obtained from each pa-
tient and was stored at −20◦C. All patients provided in-
formed consent allowing for the use of tumor specimens for
molecular and cell culture studies. The study was approved
by the Ethics Committee of the University Hospital of Turin.
2.2. Histology, Immunohistochemistry (IHC), and Immunoflu-
orescence (IF). Haematoxylin and eosin stain (H&E) was
performed on 4 μm paraffin sections.
IHC was performed on 4 μm paraffin sections using a
Ventana Full BenchMark automatic immunostainer (Ven-
tana Medical Systems Inc., Tucson, AZ, USA). UltraView
Universal DAB Detection Kit was used as detection system.
The antibodies used are listed in Table 1. Heat-induced
epitope retrieval (HIER) was performed in Tris-EDTA, pH 8
(Ventana Medical Systems). Negative controls were obtained
by omitting the primary antibody.
Double immunohistochemistry was performed using
Nestin, GFAP, and CD34 antibodies with ultraViewUniversal
Alkaline Phosphatase Red Detection Kit as chromogen (Vent-
ana Medical Systems).
IF was performed on frozen sections, NS and AC. Goat
anti-rabbit FITC-conjugated IgG and rabbit anti-mouse
TRITC-conjugated IgG antibodies were used. Cell nuclei
were stained with DAPI. The antibodies used are listed
in Table 1. Observations were made on a Zeiss Axioskop
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Table 2: Microsatellites markers used for LOH analysis.
Region STR Locus Repeat Max. het∗ PCR primers 5′ to 3 (forward/reverse)
1p
D1S508 1p36.23 (AC)n 0.812 AGCTGGGGAATATATGTNTCATATTGTGGAAGGCCAACTC
D1S496 1p36.1-p34.3 (AC)n 0.815 TCTCTATGCATCTATGCATCTATCTGCATTTGTCTGGGTTCTT
D1S2724 1p33 (AC)n 0.821 TCAAGTCCCAGGAGGATTCCACTGTGTTATTTAGCAGGAT
D1S457 1p13.3 (AC)n 0.742 GGGGGCAATAACACAAAGGAGCCTGGAGCCAAGAGTGCTA
9p
D9S157 9p22.2 (AC)n 0.849 AGCAAGGCAAGCCACATTTCTGGGGATGCCCAGATAACTATATC
D9S171 9p21.1 (AC)n 0.804 AGCTAAGTGAACCTCATCTCTGTCTACCCTAGCACTGATGGTATAGTCT
10q
D10S212 10q26.3 (AC)n 0.74 GAAGTAAAGCAAGTTCTATCCACGGAAGTAAAGCAAGTTCTATCCACG
D10S190 10q26.11 (AC)n 0.863 GTGTTTGGGTCATGGAGATGAGGCAAAGCAGGAGCA
D10S562 10q25.3 (AC)n 0.715 CCTGGCAGATGGAGGTTTCGGAGTGCTTCCTTAAAATAC
17p
TP53 Alu 17p13.1 (AAAAT)n 0.594 ACTCCAGCCTGGGCAATAAGAGCTACAAAACATCCCCTACCAAACAGC
D17S520 17p13 (AC)n 0.854 GGAGAAAGTGATACAAGGGATAGTTAGATTAATACCCACC
19q
D19S412 19q13.33 (AC)n 0.812 TGAGCGACAGAATGAGACTACATCTTACTGAATGCTTGC
D19S219 19q13.32 (AC)n 0.77 GTGAGCCAAGATTGTGCCGACTATTTCTGAGACAGATTCCCA
STR: Short Tandem Repeat.
∗Maximum heterozygosity.
fluorescence microscope (Karl Zeiss, Oberkochen, Germany)
equipped with an AxioCam5MR5c and coupled to an Imag-
ing system (AxioVision Release 4.5, Zeiss).
2.3. In Vitro Cultures. Tumor tissue was processed as previ-
ously described [24]. Culture conditions were the following:
for NS, Dulbecco’s modified Eagle’s medium (DMEM)/F-
12 with 10 ng/mL bFGF (basic fibroblast growth factor) and
20 ng/mL EGF (epidermal growth factor); for AC, DMEM
with 10% fetal bovine serum (FBS). Both cultures were
maintained at 5% O2/CO2. GBM reference cell lines were
U87-MG and 010627 (Galli R, DIBIT San Raffaele, Milan)
for both AC and NS.
All cell cultures were periodically checked for Myco-
plasma contamination (e-Myco Mycoplasma PCR Detection
kit, iNtRON Biotechnology, Korea).
For population analyses, cells were plated at 200,000 cells/
cm2, and the resulting spheres were collected every 4–6 days.
The total number of viable cells was assessed at each passage
by Trypan blue (Sigma, St. Louis, MO, USA).
Clonogenic assays were performed as previously de-
scribed [25]. Briefly, NS were dissociated into single cells and
plated into a 96-well plate for the subsphere-forming assay
by limiting dilution. Single-cell suspensions were diluted and
plated at 1-2 cells/well. After plating, cells were monitored,
and only wells containing a single cell were considered for the
analysis. Wells were scored for sphere formation following
one month of culture.
Differentiation assays were performed by mitogen with-
drawal and the addition of 3% FBS to the culture.
2.4. Tumorigenicity. It was tested by transplanting NS and
AC from each sample into NOD SCID mice (Charles River,
Calco, Italy). Two microliters of a 1 × 108 cells/mL suspen-
sion were stereotactically injected into the right striatum ac-
cording to the procedure described in Galli et al. [3]. Mouse
brains were treated with FFPE using the same procedures as
described for primary tumors. Injections were carried out at
the H. S. Raffaele, Milan.
2.5. Ethics Statement. All animals were handled in strict
accordance with good animal practice as defined by the rel-
evant international (Directive 86/609/EEC and recommen-
dation 2007/526/EC from the European community) and
national (Legislative Decree 116/92 and law n. 413/1993)
directives and according to protocols approved by the Animal
Care and Use Committee of the H. S. Raffaele (IACUC #316).
2.6. DNA Extraction. Genomic DNA was extracted from
frozen tumor samples according to a standard phenol-chlo-
roform protocol. DNA extraction from cell lines was per-
formed with the QIAmp DNA Mini Kit (Qiagen GmbH,
Hamburg, Germany) and from peripheral blood by a salting-
out procedure. The genetic analyses described below were
carried out on primary tumors, NS and AC.
2.7. Loss of Heterozygosity (LOH) Analysis. Allelic imbalances
were determined by LOH analyses of microsatellite markers.
Highly polymorphic markers were selected based on their
heterozygosity and position on the five most frequently de-
leted chromosomes in gliomas (Table 2). Microsatellites were
amplified in multiplex reactions by PCR with fluorescently
labeled primers (Applied Biosystems). Amplification was
performed with a standard touchdown protocol. Following
electrophoresis on an ABI 3130 Genetic Analyzer (Applied
Biosystems), data were collected by GeneMapper v4.0 soft-
ware (Applied Biosystems). LOHwas determined bymeasur-
ing the peak height ratio between the two alleles (allelic ratio)
in constitutive (N1/N2) and tumor (T1/T2) DNA samples.
Allelic imbalance was calculated from the ratio of N1/N2
to T1/T2. Values less than 0.5 and greater than 1.5 were
considered evidence of LOH [26].
2.8. EGFRAmplification Status. As in previous studies, EGFR
amplification status (GeneBank sequence NM 005228) was
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Figure 1: Histological and immunohistochemical aspects of phenotypic areas from which NS and AC generated. (a) High cell density,
nuclear pleomorphism, scanty cytoplasms, and visible mitoses, H&E. (b) High Ki-67/MIB.1 LI, DAB. (c) The external slope of a
circumscribed necrosis, H&E. (d) High vessel density, H&E. (e) Hypercellular perivascular cuffings. GFAP is more positive than Nestin
(f), DAB. Scale bar 50 μm.
assessed by Fragment Analysis and Capillary Electrophoresis
(CE) on an ABI 3130 Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA). INF-γ was used as reference house-
keeping gene. The amplification status of the EGFR gene
was determined by measuring the EGFR/INF-γ ratio. A ratio
greater than 2.09 was considered evidence of more than two
copies of the EGFR gene.
2.9. MGMT Promoter Hypermethylation Status. MGMT pro-
moter hypermethylation status (GeneBank sequence NM
002412) was determined by Methylation Specific Polymerase
Chain Reaction (MS-PCR) followed by CE as previously re-
ported [27]. Sodium bisulfite modification was performed
with the MethylEasy DNA Bisulphite Modification Kit (Hu-
man Genetic Signatures Pty Ltd, Macquarie Park, Sydney,
Australia) [27]. CpGenome Universal Methylated DNA
(Chemicon International Inc., Temecula, CA, USA), and
normal lymphocyte DNA samples were used as methylated
and unmethylated controls, respectively. Primer sequences
for MS-PCR and amplification conditions were previously
reported [28]. Following electrophoresis using an ABI 3130
Genetic Analyzer (Applied BioSystems), data were collected
by the GeneMapper Software v4.0 for fragment analysis (Ap-
plied BioSystems). The peak height ratio between peaks for
the methylated and unmethylated allele was determined.
Values greater than 0.1 were scored as evidence of the meth-
ylated status of the MGMT gene.
2.10. TP53, PTEN, EGFR, IDH1, and IDH2 Mutation
Analysis. The entire coding region of PTEN (exons 1–9)
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Figure 2: Immunohistochemistry of a parallel section of Figure 1. (a) Poor GFAP expression. (b) High Nestin expression. (c) SOX2 is highly
expressed in nuclei of the external slope of circumscribed necrosis. (d) REST expression, all DAB. (e) CD133-positive area, frozen section.
(f) Musashi-1-positive area. Scale bar 50 μm.
(GeneBank sequence NM 000314) and TP53 (exons 1–11)
(GeneBank sequence NM 000546), the tyrosine kinase do-
main (TK) (exons 18–24) of EGFR (GeneBank sequence
NM 005228), and codons R132 of IDH1 (GeneBank se-
quence NM 005896) and R172 of IDH2 (GeneBank se-
quence NM 002168) were investigated for variations by di-
rect sequencing. A minimum of 50 bp of each flanking in-
tronic sequence was also analyzed. All fragments were ampli-
fied by PCR using a standard touchdown protocol. Primer
sequences and PCR conditions are available on request.
Amplicons were analyzed by direct DNA sequencing on an
ABI 3130 Genetic Analyzer using the BigDye Terminator
version 1.1 Cycle Sequencing Kit. The reported nucleotide
and amino acid numbering is relative to the transcription
start site (+1) corresponding to the A of the ATG on the
corresponding GeneBank reference sequences.
To establish if each putative mutation was somatic (i.e.,
tumor specific) or germ-line, the corresponding patient’s
constitutional DNA was also analyzed when available.
2.11. Bioinformatic Analysis. In silico predictions of the puta-
tive functional effects of missense mutations in genes cod-
ing for TP53, PTEN, and EGFR amplification were deter-
mined by PMUT (http://mmb.pcb.ub.es/PMut/), PolyPhen
(http://genetics.bwh.harvard.edu/pph/), and SNAP (http://
cubic.bioc.columbia.edu/services/SNAP/) programs.
The effect of the intronic variants on splicing was eval-
uated by SpliceView (http://bioinfo2.itb.cnr.it/sun/webgene)
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Figure 3: Immunofluorescence of NS cultured in serum-free medium. (a) NS. (b) Cytoplasmic expression of CD133. (c) Musashi-1
expression in the cytoplasms. (d) Nestin expression in the cytoplasms. Nuclei are counterstained with DAPI (blue). (e) SOX2 expression
in nuclei. (f) REST expression in nuclei. Scale bar 50 μm.
and NNSplice (http://biologyhelp.awardspace.com/desc7
.php?id=14&type=biotech) software programs.
2.12. Western Blotting Analysis. Frozen tissue and cultured
cells (NS and AC) were homogenized in a lysis buffer
(50mM Tris-HCl, pH 7.4, 150mMNaCl, 1% v/v Igepal, 2%
sodium dodecyl sulfate (SDS), 0.5% sodium deoxycholate,
10mM EDTA) supplemented with Protease Inhibitor Cock-
tail (Sigma), 2mM sodium orthovanadate, and 10mM
sodium fluoride. Tissues were sonicated with three, 10-
s bursts. Whole protein extracts were quantified by BCA
Protein Assay Kit (Pierce Biotechnology, Rockford, IL,
USA) and equal amounts were resolved in 10% SDS-PAGE
gels and transferred onto PVDF membranes (Immobilon-
P, Millipore, Bedford, MA). Blots were probed with the
antibodies listed in Table 1. Membranes were then incubated
with the appropriate HRP-conjugated secondary antibodies
and proteins were detected by enhanced chemiluminescence
(Millipore). An anti-α-Tubulin antibody was used to nor-
malize sample loading and transfer. Band intensity was
quantified by densitometry using NIH Image J software
(RSB, NIMH, Bethesda, MD, USA).
3. Results
3.1. Histology. Slices from the 16 tumor samples used for
histological analyses were serial to those used for cell culture.
The following phenotypic features characterized 4 of the 6
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Figure 4: Immunofluorescence of AC cultured in serum-containing medium. (a) Monolayer of adherent cells. (b) GFAP expression in the
cytoplasms. (c) Cytoplasmic expression of GalC. (d) Cytoplasmic expression of β-III Tubulin. Nuclei are counterstained with DAPI (blue).
Scale bar 50 μm.
samples from which NS generated and 3 of the 9 samples
from which AC generated: high cell density, high number
of mitoses, a Ki-67/MIB-1 labeling index (LI) between 25%
and 30%, circumscribed necroses with pseudo-palisading,
high vessel density, and perivascular cuffings of tumor cells
(Figure 1).
3.2. Immunohistochemistry of Primary Tumors. Nestin was
variably expressed in all GBMs, but its distribution did not
completely overlap with that of GFAP. As a matter of fact,
Nestin expression was higher than GFAP expression, consid-
ering both the number of positive cells and the same cells
(Figures 2(a) and 2(b)). SOX2 and REST, which are diffusely
expressed in all GBMs, reached the highest intensity in the
areas the phenotype of which has been above described and
around vessels (Figures 2(c) and 2(d)).
3.3. Immunofluorescence of Primary Tumors (Frozen Sections).
As determined by analysis of frozen sections, CD133 and
Musashi-1 were sporadically expressed in areas of variable
size or in single cells (Figures 2(e) and 2(f)).
3.4. In Vitro Culture Assay. NS and AC were observed in
cultures from 6 (CV1, CV7, CV10, CV13, CV17, and CV20)
and 9 (CV1, CV2, CV3, CV4, CV6, CV8, CV9, CV10, and
CV17) of the 16 samples, respectively (37.5% and 56.3%).
Cells derived from CV10 primarily grew as AC, occasionally
forming cell aggregates attached to the culture plate. When
CV10 aggregates were transferred to a low-adherent culture
plate with DMEM/F-12 medium and mitogens, they gave
rise to NS. In cells derived from CV1, in addition to NS,
occasional AC were observed when cultured with DMEM/F-
12 and mitogens. Alternatively, cultures derived from CV17
developed both NS and AC in their respective media
conditions.
NS cultures were verified to contain true BTSCs by
assessing their long-term self-renewing ability by population
analysis. Cells grown in culture with growth factors prolif-
erated as nonadherent, multicellular spheres (Figure 3(a)),
whereas cells grown with serum proliferated as an adherent
monolayer with an initial heterogeneous morphology which
later became homogeneous with resemblance to fibroblasts
(Figure 4(a)) and showing astrocytic, oligodendrocytic, or
neuronal differentiation (Figures 4(b)–4(d)). Growth rates
of NS and AC are illustrated in Figures 5(a) and 5(b).
Figure 5(c) shows the different growth rates between NS and
AC of the same cell line.
The subsphere-forming assay performed by limiting
dilution demonstrated that the clonogenic efficiency of all NS
to form subspheres from individual NS cells was 7–9%.
By differentiation assays NS demonstrated their multipo-
tency showing after 7 days from the addition of 3% serum
an astrocytic, oligodendrocytic and neuronal differentiation
(Figures 6(a)–6(c)). Upon intracranial transplantation, NS
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Figure 5: Growth rates of NS and AC. (a) Growth curves of NS cultured in serum-free medium supplemented with mitogens from CV1,
CV7, CV10, CV13, CV17, CV20, and reference cell lines U87-MG and 010627. (b) Growth curves of AC cultured in serum containing
medium from CV2, CV3, CV4, CV6, CV8, CV9, CV10, CV17 (CV1 is not included), and reference cell lines U87-MG and 010627. (c)
Comparison between NS and AC curves.
developed tumors in mice, whereas AC did not developed
tumors or showed a reduced tumorigenicity in two cases
(data not shown), demonstrating that NS populations in-
cluded true BTSCs. Details of intracranial transplantations
will be discussed in a separate manuscript.
3.5. Immunofluorescent Analysis of Cell Lines. NS and AC
showed different antigenic expression patterns. Nestin was
strongly expressed in NS, along with SOX2 and REST, where-
as CD133 and Musashi-1 were only sporadically expressed
(Figures 3(b)–3(f)). GFAP was expressed in cells from only
one sample (CV7). AC, in contrast, showed decreased Nestin
expression and increased GFAP expression when compared
with NS. Both CD133 and Musashi-1 expression was almost
completely absent in AC. Nuclear expression of SOX2 and
REST was lower in AC when compared to NS.
Comparisons of primary tumors, NS and AC are shown
in Table 3. The expression of antigens indicative of stemness
was highest in primary tumors and NS, whereas the expres-
sion of antigens indicative of differentiation was highest in
AC.
3.6. Molecular Genetics. The derivation of NS and AC from
the respective primary tumors was confirmed by genotyping
of the 13 microsatellite markers used for LOH analysis.
Genetic alterations in primary tumors and in the
matched NS or AC are summarized in Table 4. Their fre-
quency is consistent with the primary nature of GBMs. No
Journal of Oncology 9
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Figure 6: Immunofluorescence of differentiation of NS after addition of 3% serum. (a) Cytoplasmic expression of βIII-Tubulin (red). (b)
Cytoplasmic expression of GFAP (green). (c) Cytoplasmic expression of GalC (red). Nuclei are counterstained with DAPI (blue). Scale bar
50 μm.
significant differences in the frequency of genetic or epige-
netic alterations were observed between primary tumors gen-
erating cell lines and those not generating cell lines. In addi-
tion, no differences were observed between primary tumors
generating NS or AC. LOH on chromosomes 1p, 9p, 10q,
17p, and 19q, EGFR amplification, MGMT promoter hyper-
methylation as well as PTEN and TP53 mutations was iden-
tified with similar frequency in primary tumors and NS,
but not in AC. In primary tumors, PTEN mutations were
detected in 56.2% of cases, whereas only 31.2% of cases
showed TP53 mutations. The TK domain of the gene coding
for EGFR was found to be mutated in only one primary
tumor (CV6) generating AC. This previously undescribed
mutation was a somatic synonymous nucleotide substitution
(c.2904C > T, p.F968F). All observed nucleotide sequence
variations are reported in Table 5. No point mutations were
identified in codons R132 or R172 of IDH1 and IDH2 genes,
respectively.
With respect to LOH analysis, the specific spectrum of
LOH present in primary tumors was detected only in NS.
LOH of 10q was present in all primary tumors, followed
by LOH of 9p in 8 of the 16 cases (50%). LOH of 1p, 17p,
and 19q was observed only occasionally. The allelic imbal-
ance was partial in all primary tumors and complete in NS
(Figure 7). No detectable LOH was identified in AC. In line
with these data, MGMT was hypermethylated in 50% of
primary tumors and in 63.7% of NS. Remarkably, AC from
CV10 showed a molecular profile typical of NS.
3.7. Western Blotting Analysis. Western blotting analysis con-
firmed a higher prevalence of antigens indicative of stemness
in primary tumors and NS when compared to AC, in which
antigens indicative of differentiation were more highly ex-
pressed. MGMT expression was consistent with the MGMT
promoter hypermethylation status (Figure 8(a)). Densito-
metric analyses of the antigens studied in NS, AC, and the
corresponding primary tumors are reported in Figures 8(b)
and 8(c).
4. Discussion
One important question is whether GBMs are heterogeneous
with respect to their BTSC content. Basically, it has been
demonstrated that different subsets of BTSCs with different
proliferative, clonogenic, and tumorigenic properties exist in
GBMs [3]. Moreover, chemosensitivity of highly infiltrative
GBMs has been demonstrated to be associated with a stem
cell-like phenotype, that is, with the expression of Nestin,
Vimentin, and Musashi-1 [3, 29]. In a study no difference
was found among several samples from the same tumor as for
their BTSC content [22], but in another study the existence
of at least two types of BTSCs from different regions of the
same tumor has been demonstrated; they showed different
genetic anomalies and tumorigenic potentials, even though
the cells were considered to derive from common ancestors
[21]. The demonstration of BTSCs largely depends on the
technical procedures, but in most studies only approximately
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Table 3: Primary tumors, NS and AC. Immunohistochemistry and immunofluorescence.
(a)
Antibodies
FFPE sections
CV1 CV7 CV10 CV13 CV17 CV20
GFAP + + + + + ±
βIII-Tubulin − − + − − −
GalC − − − − − −
Nestin ++ ++ + ++ ++ ++
CD133 −∗ −∗ ±∗ ±∗ ±∗ +
Musashi-1 −∗ −∗ ±∗ ±∗ −∗ +
SOX2 ++ ++ ++ ++ ++ ++
REST ++ ++ ++ ++ ++ ++
Antibodies
NS
CV1 CV7 CV10 CV13 CV17 CV20
GFAP ± + ± − − −
βIII-Tubulin − + + − − ±
GalC − + ± − − ±
Nestin + + + + + ±
CD133 + + + ± − −
Musashi-1 + + ± ± − −
SOX2 + + + + + +
REST + + + + + +
(b)
Antibodies FFPE sections
CV1 CV2 CV3 CV4 CV6 CV8 CV9 CV10 CV17
GFAP ++ + ++ + + + + + +
βIII-Tubulin ± − + − − − − − −
GalC − − − − − − − − −
Nestin + + + + + + + + +
CD133 −∗ −∗ ±∗ ±∗ ±∗ −∗ − − −
Musashi-1 −∗ −∗ ±∗ ±∗ −∗ −∗ − − −
SOX2 + + + + + + + + +
REST + + + + + + + + +
Antibodies
AC
CV1 CV2 CV3 CV4 CV6 CV8 CV9 CV10 CV17
GFAP + + + + + + + + +
βIII-Tubulin + + + − ± ± − − +
GalC − + + − + ± − − +
Nestin + + + + + + + + +
CD133 − − + − ± − − − +
Musashi-1 ± − + − ± ± − − +
SOX2 − − − − +◦ ± +◦ + +◦
REST − − − + +◦ + +◦ − +◦
∗
Tested by IF on primary tumor frozen sections. ◦Cytoplasmic staining. +Moderate expression intensity. ++High expression intensity. ± Barely visible. −
Negative.
30% of GBMs generate NS [22]. Selecting differently glioma
initiating cells, for example by autofluorescence, these can be
found in all glioma types [30].
In our GBM series, the development of NS in culture is
largely dependent on the occurrence in primary tumors of
what is known as the most malignant phenotype of GMB,
composed of small hyperchromatic and rapidly dividing
cells, with vessel hyperdensity and circumscribed necroses
[23]. In the present study, the most important observation
is that the frequency of the genetic and epigenetic alterations
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Table 4: Frequency of genetic and epigenetic alterations in primary tumors, NS and AC.
Molecular marker Primary GBM (%) NS (%) AC∗ (%)
LOH 1p, 9p, 10q, 17p, 19q 16 (100) 6 (100) 0 (0)
EGFR amplification 8 (50) 3 (45) 0 (0)
MGMT hypermethylation 9 (50) 4 (66.7) 0 (0)
TP53 mutations 5 (31.2) 3 (50) 0 (0)
PTEN mutations 9 (56.2) 4 (66.7) 2 (22.2)
EGFR mutations 1 (<1) 0 (0) 0 (0)
p.R132 IDH1 0 (0) 0 (0) 0 (0)
p.R172 IDH2 0 (0) 0 (0) 0 (0)
∗
An exception is CV10 in which NS generated from AC. AC showed the same molecular profile of NS.
Table 5: Spectrum of the identified sequence variations.
Gene CDS variation AA variation Location refSNP ID Function Number of heterozygous patients
TP53
IVS3−29C>Aa p.? IVS3 rs17883323 1
c.215G>C p.R72P Exon 4 rs1042522 Functional polymorphism 6
IVS4+5G>Ca,d p.? IVS4 de novo Splice variant 1
c.388C>Ad p.L130I Exon 5 de novo Missense 1
c.473G>Tb,c p.R158L Exon 5 Missense 1
c.527G>Ab,c p.C176Y Exon 5 Missense 1
c.639A>Gb p.R213R Exon 6 rs1800372 Nonsense 2
IVS6+31A>Ga p.? IVS6 rs34949160 No splice variant 3
IVS6+62G>Aa p.? IVS6 rs1625895 No splice variant 7
IVS6−36G>Ca p.? IVS6 rs17880604 No splice variant 1
c.713G>Ab,c p.C238Y Exon 7 Missense 1
IVS7−35A>Ga,d p.? IVS7 de novo No splice variant 1
c.817C>Tb,c p.R273C Exon 8 rs1625895 Missense 2
c.832C>Tb,c p.P278S Exon 8 Missense 1
PTEN
c.170 171insTc p.L57fs∗5 Exon 3 Frame-shift and stop codon 1
IVS3+1G>Ta,c p.? IVS3 No splice variant
c.328C>Tc p.Q110∗ Exon 5 Stop codon 1
c.371G>Ad p.C124Y Exon 5 de novo Missense 1
c.388C>Tc p.R130∗ Exon 5 Stop codon 1
c.395G>Ac p.G132D Exon 5 Missense 1
c.538T>Cd p.Y180H Exon 6 de novo Missense 1
c.541delCd p.L181fs∗1 Exon 6 de novo Frame-shift and stop codon 1
IVS6+2T>Ga p.? IVS6 de novo Splice variant 1
c.754G>A p.D252N Exon 7 de novo Missense 1
IVS8+32T>Ga p.? IVS8 rs555895 No splice variant 8
c.954 957delTACTc p.L318fs∗2 Exon 8 Frame-shift and stop codon 1
c.1061C>Td,e p.P354L Exon 9 Missense 1
EGFR
IVS18+19G>Aa p.? IVS18 rs17337107 4
IVS18+100C>Ta p.? IVS18 rs17290336 2
IVS19−60T>Ca p.? IVS19 rs10241451 5
c.2361A>G p.Q787Q Exon 20 rs1050171 Nonsense 11
c.2508C>T p.R836R Exon 21 rs17290559 Nonsense 1
c.2709C>T p.T903T Exon 23 rs1140475 Nonsense 6
c.2904C>Td p.F968F Exon 24 de novo Nonsense 1
aThe numbering of intronic variations is relative to the first (+) or the last (−1) nucleotide of the corresponding intron.
bPreviously reported as somatic mutation in gliomas or glioma cell lines at the International Agency for Research on Cancer (http://www-p53.iarc.fr/).
cPreviously reported in gliomas or glioma cell lines in the Catalogue of Somatic Mutations in Cancer (http://www.sanger.ac.uk/genetics/CGP/cosmic/).
dVariations identified de novo in gliomas in the present study.
eAlready present in the patient’s constitutive DNA.
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Figure 7: Genetic analysis for CV17 primary tumor, NS, AC, and brain tumor developed in mouse after transplantation of CV17 NS.
LOH on CV17 primary tumor, NS, AC, constitutive DNA, and on brain tumor developed after NS transplantion into Nod Scid mice.
Electropherograms show allelic imbalances for the following microsatellite markers: D1S457 (green), D9S171 (red), D10S562 (red), TP53-
Alu (green), and D19S412 (blue). For all markers, primary tumor shows a partial allelic imbalance in comparison with the constitutive DNA,
which is complete in NS, with the exception of D1S457 and TP53-Alu, and in CV17 mouse brain tumor. Arrows indicate, for each marker,
the allelic imbalance in primary tumor, NS and in mouse brain tumor.
is very similar between primary tumors and NS, showing a
strong genotypic concordance. This is particularly remark-
able in the case of LOH profiles, which are present with the
same spectrum in both primary tumors and NS, but not in
AC. This observation is consistent with previous data [31].
The allelic imbalance was partial in primary tumors and
complete in NS. In AC, no detectable genetic or epigenetic al-
teration similar to that of the corresponding primary tumor
was observed, with the exception of occasional PTEN muta-
tions. The MGMT hypermethylation status and the EGFR
amplification status showed a similar frequency between
primary tumors and NS, but not between primary tumors
and AC. The same is true for the mutation spectrum of
TP53 and PTEN genes. In 3 of our cases, both NS and AC
developed from the same tumor sample indicating that cells
with different potential can coexist in the same tumor. Inter-
estingly, in 1 of these 3 cases, AC generating NS showed the
same molecular profile as NS.
The prevalence of Nestin upon GFAP and the expression
of stemness antigens in perivascular cuffings and in areas
with vessel hyperdensity of primary tumors is in line with
the preference of BTSCs for perivascular niches [32–34].
The latter recapitulate normal NSCs and the vasculature
of developing nervous system [35, 36]; on the other hand,
BTSCs in gliomas mediate vascular proliferation via VEGF
[37, 38].
The different behavior of NS and AC may be due to
showing the former full stemness properties and appearing
the latter as the product of cell differentiation. NS could be
transformed NSCs from germinal zones, subventricular zone
(SVZ), or subgranular zone (SGZ), or from dedifferentiated
elements of the astrocytic lineage [39], whereas AC could
Journal of Oncology 13
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Figure 8: Western blotting analysis of the different antigens studied in cell lines (NS and AC) and in primary tumors. (a) Stemness antigens
and differentiation antigens prevail in NS and AC, respectively. (b) Densitometric quantification of bands in NS and in the corresponding
primary tumors. (c) Densitometric quantification of bands in AC and in the corresponding primary tumors.
14 Journal of Oncology
Neural stem cells Brain tumor stem cells
Progenitors
Precursors
Oligodendrocytes Astrocytes
The whole tumor
Neurons
Progressive appearance
of more malignant
new clones
Precursors
D
if
fe
re
n
ti
at
io
n
D
if
fe
re
n
ti
at
io
n
Stemness
Progenitors
Figure 9: Scheme of a hypothetical distribution of stemness during differentiation and dedifferentiation. Stemness decreases from the stage
of neural stem cells toward progenitors and adult cells. Conversely, in tumors it increases to a maximum in the stage of brain tumor stem
cells.
represent a differentiating cell type. Intermediated behaviors
have been observed in our material, as it has been already
shown [20].
The generation of NS from a tumor sample mostly when
it shows the mentioned phenotype may suggest that BTSCs
arise from or are contained in the novel, proliferating and
dedifferentiated clones which develop following mutation
accumulation or epigenetic events during malignant trans-
formation and substitute the predecessors via competitive
selection [10]. This hypothesis, previously considered [3,
8, 10, 11], regards dedifferentiated cells as regressed to an
embryonic state reacquiring a stem cell-like status. Embry-
onic regression has been previously invoked, for example, for
reactive astrocytes reexpressing Nestin [40, 41].
Our observations concern a very important debated
question, that is, the cell composition of a starting tumor
tissue. It is not clear whether a major role is played by the
occurrence of BTSCs in the tissue or by culture conditions.
On the other hand, a clear distinction between NS and AC
is still debated concerning self-renewal, clonogenicity and
tumorigenicity, and intermediate stages between them exist;
terms such as semiadherent cells have been coined for them
[20]. This is confirmed by the behavior of CV1, CV10, and
CV17 of our series.
Stemness, therefore, might not be a property of a specific
cell type, but a status which encompasses the early steps of
the cytogenesis. It is conceivable that in the process of dif-
ferentiation during cytogenesis there is a point, represented
by progenitors, beyond which stemness ceases. In the same
way, considering the process of tumor cell dedifferentiation
from more differentiated stages, through the development of
new clones there should be a point beyond which stemness
reappears. From the different stages of differentiation and
dedifferentiation, different stemness potentials could be
recognized, explaining intermediate properties (Figure 9). A
similar problem has been presented and exhaustively dis-
cussed in relation to leukemias [42].
The high expression of SOX2 and REST in primary tu-
mors and NS is a stemness property. In our samples, SOX2
not only correlated with the malignancy grade, but it was
also overexpressed in the GBM phenotype from which NS
could be generated and even amplified as in NS [43].
SOX2 is therefore a proliferation and stemness factor. REST
has been shown to display tumor-suppressor activity [44]
and oncogenic functions in medulloblastoma [45]. REST is
overexpressed in NSC and in medulloblastomas [46, 47]. We
did not find in our samples even a slight REST amplification
[48]; however, it is overexpressed in the primary tumor phe-
notype generating NS. The most commonly held position is
that REST could maintain stem cell status [49].
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